Biotech Knockoffs
March 16, 2007 | Sandoz Pharmaceuticals, the generics business of Swiss pharma giant Novartis, makes good money selling generics for just one-fifth the price of their branded equivalent. But biotech drugs are inherently more complex than their chemical counterparts. That could mean that any future biotech knockoffs might be only approximations of the original, not true generics that pharmacists could substitute for a branded equivalent. Story in Forbes.
Feeds